Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Eli Lilly (NY:LLY)

883.93 +21.07 (+2.44%)
Streaming Delayed Price Updated: 11:06 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
1 Unpopular Stock That Deserves Some Love and 2 We Find Risky
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
Are These GLP-1 Trial Results About to Send Eli Lilly's Stock Soaring?
The pharmaceutical company had a clinical setback earlier this year, but that's now in the rearview mirror. 
Via The Motley Fool
Where Will Recursion Pharmaceuticals Be in 5 Years?
Could investing in this stock be an underrated way to profit from the rapidly expanding AI industry? 
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
Immuneering Corporation's Stock Takes a Hit Amidst Funding Round Despite Promising Clinical Data
Boston, MA – September 27, 2025 – Immuneering Corporation (NASDAQ: IMRX) experienced a significant downturn in its stock value on September 25, 2025, with shares declining by approximately 13.3%. This... 
Via MarketMinute
Pharmaceutical Tariffs ‘A Light At The End Of The Trump Tunnel’ For Big Pharma, Says Jefferies
Via Stocktwits
Topics Government
Eli Lilly Terminates Study Of Bimagrumab In Obesity
Via Stocktwits
Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?
The company continues to improve its pipeline. 
Via The Motley Fool
Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility
September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025.... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Healthcare Sector Reels: A Deep Dive into Thursday's -1.67% Plunge
The healthcare sector experienced a significant downturn on Thursday, September 25, 2025, shedding a notable -1.67% of its value and sending ripples of concern through the broader financial markets.... 
Via MarketMinute
Topics Economy
Amgen Expands US Manufacturing Network Amid New Tariff Policy
Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network. 
Via Benzinga
Topics Government World Trade
Your AstraZeneca Medicine Could Be Cheaper As Much As 70%
AstraZeneca Plc (NASDAQ: AZN) launched AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent... 
Via Benzinga
Consumers Splurge, Intel, GlobalFoundries, Lilly, Paccar, American Woodmark Benefit From New Tariffs
To gain an edge, this is what you need to know today. 
Via Benzinga
Stock Market Soars: Inflation Data Aligns with Expectations, Igniting Hopes for Continued Fed Easing
New York, NY – September 26, 2025 – U.S. stock market futures, including the Dow, S&P 500, and Nasdaq, registered notable advances today, signaling a robust open after the release of August's inflation... 
Via MarketMinute
Topics Bonds Economy Government
3 Strong-Buy Dividend Growth Stocks
All three of these stocks pay fast-growing dividends. 
Via The Motley Fool
Trump's 100% Drug Tariffs 'A Meaningful Commercial Hit' For Americans, But 'Loopholes' Could Blunt Impact, Says Analyst
President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly... 
Via Benzinga
Topics Government World Trade
FDA Approves Eli Lilly's Drug For Advanced Breast Cancer
Eli Lilly secured FDA approval for breast cancer drug Inluriyo and EU clearance for Alzheimer's therapy Kisunla following strong Phase 3 data. 
Via Benzinga
Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock?
The pharmaceutical giant is again plunging headfirst into weight-loss drug development. 
Via The Motley Fool
Topics Intellectual Property
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know.
Recent data from a head-to-head trial was positive for Eli Lilly, but it's not the whole story. 
Via The Motley Fool
Why Is Eli Lilly’s Stock Rising Premarket?
The European Commission cleared its Alzheimer’s drug Kisunla, adding another country to the company’s list where the once-monthly therapy is approved. 
Via Stocktwits
Topics Government World Trade
Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America
Via Stocktwits
Topics Government
Eli Lilly (LLY) Stock Trades Down, Here Is Why
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.1% in the afternoon session after the company halted a mid-stage clinical trial for its experimental drug, bimagrumab, which was... 
Via StockStory
Topics Artificial Intelligence
Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move?
Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it... 
Via Benzinga
AI Takes Center Stage in Biodefense: DARPA's NODES Program Promises to Revolutionize Pandemic and Biowarfare Protection
In a groundbreaking leap for global health security, the Defense Advanced Research Projects Agency (DARPA) officially launched its Network of Optimal Dynamic Energy Signatures (NODES) program in July... 
Via MarketMinute
Topics Artificial Intelligence
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. 
Via Benzinga
Does This Acquisition Make Pfizer Stock a Great Buy?
There's an opportunity to get in on the weight-loss drug craze at a reasonable price. 
Via The Motley Fool
Topics Death Intellectual Property
1 Reason Novo Nordisk (NVO) Is 1 of the Best Healthcare Stocks You Can Buy Today
The latest data from the company's oral weight loss drug is bullish for the stock. 
Via The Motley Fool
Topics Economy
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering.
Investors once speculated that Pfizer might consider acquiring Viking. 
Via The Motley Fool
3 Small-Cap Stocks We Keep Off Our Radar
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
Healthcare Sector Grapples with 5% Slump in 2025: A Deep Dive into Market Underperformance
The healthcare sector finds itself in turbulent waters in 2025, registering a concerning 5% slump and significantly lagging the overall S&P 500 index. This downturn marks a continuation of a multi-year... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.